Transcode Therapeutics, Inc. (RNAZ) - 10-K Summary
Business Context and Reporting Period
Company: Transcode Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Period Ended: December 31, 2025
Business Overview: Transcode is a clinical-stage biopharmaceutical company focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is an antisense inhibitor of microRNA-10b designed to treat metastatic disease. The company also develops a cancer vaccine (Seviprotimut-L) and an oncolytic immunotherapy platform.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(34.7) million | $(16.8) million |
| Operating Expenses | $28.0 million | $15.7 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $17.8 million | $5.8 million |
| Accumulated Deficit | $(97.9) million | $(63.2) million |
| Intangible Assets (IPR&D) | $114.3 million | $0 |
| Goodwill | $25.7 million | $0 |
Note: The company has not generated any revenue to date. Expenses are primarily driven by research and development (R&D) and general and administrative (G&A) costs.
Material Changes vs. Prior Period
- Acquisition of Polynoma: On October 8, 2025, Transcode acquired Polynoma, LLC (via ABCJ, LLC) for approximately $140 million in consideration (primarily Series A Preferred Stock and common stock). This added Seviprotimut-L, a Phase 2 melanoma vaccine, to the pipeline and resulted in the recognition of $114.3 million in In-Process Research and Development (IPR&D) assets and $25.7 million in goodwill.
- Increased Operating Loss: Net loss more than doubled to $34.7 million in 2025 compared to $16.8 million in 2024. This was driven by a $3.7 million increase in R&D expenses and an $8.8 million increase in G&A expenses, the latter largely due to $8.8 million in acquisition-related transaction costs.
- Financing Activities: The company raised approximately $31.5 million in net cash from financing activities in 2025, primarily through the issuance of Series B Preferred Stock ($22.7 million net) and common stock ($8.9 million net), compared to $16.4 million in 2024.
- Non-Cash Items: Significant non-cash charges included a $9.3 million loss on the change in fair value of warrant liabilities and a $1.6 million accrual of paid-in-kind dividends on Series A Preferred Stock.
Guidance, Outlook, and Risks
- Clinical Progress: The Phase 1a clinical trial for TTX-MC138 was completed in October 2025, meeting its primary safety endpoint. The company plans to commence a Phase 2a clinical trial in the first half of 2026. A collaboration with Quantum Leap Health Care Collaborative was announced for a Phase 2a trial in colorectal cancer.
- Liquidity and Going Concern: As of December 31, 2025, the company held $17.8 million in cash. Management believes this is sufficient to fund operations through approximately year-end 2026. However, the independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional capital.
- Recent Financing (Subsequent Event): On April 7, 2026, the company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing for the sale of up to $14 million of common stock and the issuance of convertible notes for up to $6 million.
- Key Risks:
- Capital Requirements: The company requires substantial additional funding to advance clinical trials and commercialize products. Failure to secure financing could force delays or termination of programs.
- Delisting Risk: The company faces potential delisting from Nasdaq if it fails to maintain listing requirements, though it received compliance notification in June 2025.
- Internal Controls: The company identified material weaknesses in its internal control over financial reporting related to the Polynoma acquisition and historical accounting processes.
- Stockholder Approval: Conversion of Series A, B, and C Preferred Stock into common stock is subject to stockholder approval, which has not yet been obtained.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.8 million cash balance against the projected burn rate for the planned Phase 2a trials and integration of Polynoma.
- Financing Terms: Review the specific terms of the April 2026 SEPA with Yorkville and the convertible notes, including dilution caps and conversion pricing.
- Stockholder Approval: Monitor the status of the required stockholder votes to approve the conversion of Series A, B, and C Preferred Stock, which is critical for liquidity and capital structure.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Acquisition Integration: Evaluate the progress of integrating Polynoma's operations and the potential synergies between TTX-MC138 and Seviprotimut-L.